Jushi Holdings (JUSHF) Cost of Revenue (2021 - 2026)
Jushi Holdings' (JUSHF) quarterly Cost of Revenue came in at $36.6 million in Q1 2026, down 3.98% year-on-year from $38.1 million in Q1 2025, and down 7.98% on a QoQ basis from $39.7 million in Q4 2025.
Jushi Holdings (JUSHF) Cost of Revenue (2021 - 2026) Analysis & Trends
Jushi Holdings (JUSHF) has 6 years of Cost of Revenue data on file, last reported at $36.6 million in Q1 2026.
- On a quarterly basis, Cost of Revenue fell 3.98% year-over-year to $36.6 million in Q1 2026; TTM through Mar 2026 was $147.4 million, a 2.26% increase from a year earlier, with the FY2025 full-year figure at $148.9 million, up 6.97% from the prior year.
- Cost of Revenue for Q1 2026 stood at $36.6 million, down from $39.7 million in the prior quarter.
- Over the last five years, Cost of Revenue for JUSHF reached as high as $54.9 million in Q4 2022 and fell as low as $32.0 million in Q2 2024.
- Historically, Cost of Revenue has averaged $39.2 million across 5 years, with a median of $38.1 million in 2025.
- Across the five-year window, Cost of Revenue jumped 76.41% in 2022 and fell 26.09% in 2023, its largest moves.
- Year by year, Cost of Revenue stood at $54.9 million in 2022, then retreated by 26.09% to $40.6 million in 2023, then dropped by 0.24% to $40.5 million in 2024, then declined by 1.8% to $39.7 million in 2025, then slipped by 7.98% to $36.6 million in 2026.
- Per Business Quant data, the three most recent Cost of Revenue figures were $36.6 million in Q1 2026, $39.7 million in Q4 2025, and $35.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 2.01 Bn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | 641.00 Mn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | 2.59 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 133.40 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 2.36 Bn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 13.80 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 586.00 Mn |
| 10 | Jushi Holdings | 81.25 Mn | 41.54 Mn | 29.88 Mn | 36.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 36.56 Mn |
| Mar 31, 2026 | 36.56 Mn |
| Dec 31, 2025 | 39.72 Mn |
| Dec 31, 2025 | 39.72 Mn |
| Sep 30, 2025 | 35.02 Mn |
| Sep 30, 2025 | 35.02 Mn |
| Jun 30, 2025 | 36.12 Mn |
| Jun 30, 2025 | 36.12 Mn |
| Mar 31, 2025 | 38.07 Mn |
| Mar 31, 2025 | 38.07 Mn |
| Dec 31, 2024 | 40.45 Mn |
| Dec 31, 2024 | 40.45 Mn |
| Sep 30, 2024 | 33.61 Mn |
| Sep 30, 2024 | 33.61 Mn |
| Jun 30, 2024 | 32.03 Mn |
| Jun 30, 2024 | 32.03 Mn |
| Mar 31, 2024 | 33.13 Mn |
| Mar 31, 2024 | 33.13 Mn |
| Dec 31, 2023 | 40.55 Mn |
| Dec 31, 2023 | 40.55 Mn |